湖南地区2型糖尿病视网膜病变易感性因素初步研究
|
摘要
目的：
研究湖南地区2型糖尿病视网膜病变(diatetic retinopathy,DR)遗传及环境易感因素；筛选糖尿病视网膜病变发生的高危人群。
(1)采用荟萃分析方法,搜寻黄种人中与糖尿病视网膜病变发生相关的血管内皮生长因子(vascular endothelial growthfactor,VEGF)单核苷酸多态性位点。
(2)探讨湖南地区人群中VEGF单核苷酸多态性位点与糖尿病视网膜病变易感性的关联性。
(3)探讨血清中VEGF蛋白总量,亚型VEGF165及其异构体VEGF165b含量与糖尿病视网膜病变的相关性。
(4)采用病例对照及logistic回归分析比较VEGF单核苷酸多态性位点、VEGF蛋白及其他人口学特征和生化指标,探讨糖尿病视网膜病变发生的高危因素。
方法：
(1)回顾2012年3月前有关VEGF单核苷酸多态性与糖尿病视网膜病变的所有英文文献。系统性检索及获取原始文献、制定纳入及排除标准；将单核苷酸多态性位点与糖尿病视网膜病变相关的实验数据进行荟萃分析。
(2)根据荟萃分析显示黄种人中有意义的VEGF单核苷酸多态性位点,采用病例对照方法,使用限制性片段长度多态性聚合酶链反应(PCR-RFLR)检测其在湖南地区正常人、糖尿病无视网膜病变患者(diabetic without retinopathy, DWR)、糖尿病视网膜病变患者(diabetic retinopathy, DR)的分布,通过卡方检验统计分析其在各组间的分布差异。
(3)采用病例对照方式,使用酶联免疫吸附测定法检测湖南地区正常人,糖尿病无视网膜病变患者,糖尿病视网膜病变患者的血清中VEGF总量,亚型/EGF165及其异构体VEGF165b含量,通过成组T检验及线性回归分析统计分析其含量在各组间的分布差异,及与、/EGF单核苷酸多态性位点及环境因素间的关联性。
(4)采用病例对照方式,统计糖尿病无视网膜病变患者,糖尿病视网膜病变患者的人口学特征及生化指标的相关数据及VEGF单核苷酸多态性位点及VEGF蛋白表达,进行成组T检验及logistic回归分析,探讨糖尿病视网膜病发生的高危易感因素。
结果：
(1)荟萃分析结果：
VEGF rs699947共显性模型-杂合型／野生型(CAVs CC)与DR发病风险存在相关性(I2=64%, OR=1.2795%CI [1.05,1.54], P=0.02),尤其在黄色人种中(I2=38%, OR=1.4695%CI [1.17,1.82], P=0.0007)。其它模型与DR发病无显著相关性(P>0.05)
VEGF rs1570360各模型在各色人种中与DR的发病无显著相关性(P>0.05)。
VEGF rs2010963亚组分析：黄色人种组隐性模型(CC V s GC+GG)显示与DR的发病相关(I2=60%, OR=1.2895%CI [1.01,1.63], P=0.04); PCR-RFLR测序方式组隐性模型(CC V s GC+GG)与DR的发生明显相关(I2=46%, OR=1.5095%CI [1.05,2.14], P=0.03)
VEGF rs3025039共显性模型-纯和型／野生型(TT Vs CC)与DR发病风险存在相关性(I2=50%, OR=2.4795%CI [1.11,5.51], P=0.03),特别是在黄色人种中(I2=51%, OR=3.5395%CI [1.35,9.26], P=0.01)。隐性模型(TT Vs CT+CC)白色人种与DR发病无明显相关性(P=0.05),在黄色人种中示与DR的发生相关(I2=33%, OR=3.1995%CI [1.21,8.42], P=0.01);其它各模型与DR的发病无明显相关性(P>0.05)。
(2)本省人群中DWR组与DR组VEGF基因多态性位点基因型频率及等位基因频率：
VEGF基因rs699947位点：DR组AA基因型分布频率为14.8%,DWR组为4.3%；CC基因型DR组为48.1%,DWR组为60.9%(P=0.04,<0.05),其等位基因A频率在DR组为33.3%,DWR组为21.7%(P=0.016,<0.05)。携带rs699947AA基因型的糖尿病患者发生DR的危险性较rs699947CC基因型及CA基因型携带者高3.83倍(OR=3.83)。
VEGF基因rs833061位点：DR组CC基因型分布频率为16.0%,DWR组为4.3%；TT基因型DR组为45.7%,DWR组为58.7%(P=0.025,<0.05),其等位基因C频率在DR组为35.2%,DWR组为22.8%(P=0.011,<0.05)。携带rs833061CC基因型的糖尿病患者发生DR的危险性较rs833061TT基因型及TC基因型携带者高4.21倍(OR=4.21)。
VEGF基因rs13207351位点：基因型频率及等位基因频率在研究组和对照组间的差异无明显统计学意义(P>0.05)。携带rs13207351GG基因型、GA基因型及AA基因型的糖尿病患者发生DR的危险性没有明显差别。
VEGF基因rs2010963位点：DR组CC基因型分布频率为21.0%,DWR组为9.8%。GG基因型DR组为28.4%,DWR组为42.4%(P=0.049,<0.05),其等位基因C频率在DR组为46.3%,DWR组为33.4%(P=0.017,<0.05)。携带rs2010963CC基因型的糖尿病患者发生DR的危险性较rs2010963GG基因型及GC基因型携带者高2.45倍(OR=2.45)。
VEGF基因rs3025039位点：基因型频率及等位基因频率在研究组和对照组间的差异无明显统计学意义(P>0.05)。携带rs3025039CC基因型、CT基因型及TT基因型的糖尿病患者发生DR的概率没有明显统计差异。
(3) VEGF蛋白总量、VEGF165含量和VEGF165b含量：
1)正常对照组中血清VEGF总量为44.47±3.42(pg/ml), DWR组血清VEGF总量为57.74±11.23(pg/ml), DR组59.25±11.62(pg/ml),DWR组及DR组的VEGF总量都较正常对照组升高(P<0.05),但DWR组与DR组之间VEGF总量没有明显的统计学差异(P>0.05)。
2)正常对照组中VEGF165含量为15.89±1.31(pg/ml), DWR组为22.68±4.52(pg/ml); DR组为27.43±7.29(pg/ml),与正常对照组比具有统计学意义(P<0.05)；且VEGF165在D WR组及DR组之间也有显著差异(P=0.025)。
3)VEGF165b在血中的含量在正常对照组为9.25±0.82(pg/ml); DWR组为6.97±1.46(pg/ml); DR组为5.43±2.35(pg/ml).其含量在三组之间呈现逐渐降低的趋势,差异具有统计学意义(P<0.05)。VEGF165及VEGF165b的比值在三组间出现变化,比值逐渐增大(1.72、3.25、5.05)。
4)蛋白总量与基因位点：携带rs2010963CC基因型人群其血中VEGF蛋白含量较GG基因型及GA型显著增高(CC基因型VEGF蛋白含量为62.59±13.71(pg/ml),GA基因型蛋白含量为53.27±10.37(pg/ml),GG基因型蛋白含量为50.85±10.59(pg/ml));CC基因型与GG基因型及GC基因型比较均具有统计学上的显著性差异,P<0.05),其他各SNP位点各基因型之间无明显统计学差别(P>0.05)。
(4)糖尿病视网膜病变易感因素分析：
1)DWR组及DR组之间的人口学特征及生化指标的相关数据进行成组T检验,发现收缩压、舒张压、糖化血红蛋白及肌酐值在两组之间存在显著的统计学差异(P<0.05)。
2)logistic回归分析：收缩压高于160mmHg的糖尿病患者发生DR的危险性较低于130mmHg的高7.5倍,舒张压高于90mmHg的糖尿病患者发生DR的危险性较低于90mmHg的高2倍。HbAIC含量高于14.0%的糖尿病患者发生DR的危险性较低于8.0%的高11.50倍。肌酐值高于100mmol/L的糖尿病患者发生DR的危险性较低于60mmol/L的高出5.5倍。携带rs2010963CC基因型糖尿病患者发生DR的危险性较GG基因型患者高3.2倍。VEGF165含量高于28.0mmol/L的糖尿病患者发生DR的危险性较低于28.0mmol/L的患者高9.3倍,而VEGF165b含量高于5.0mmol/L的糖尿病患者发生DR的危险性较低于5.0mmol/L的患者明显降低(OR=0.013),VEGF165b对于糖尿病患者有明显保护作用。
结论：
(1)黄色人种中VEGF rs699947的共显性模型(C A Vs C C)、 VEGF rs2010963隐性模型(CC Vs GC+GG)及VEGF rs3025039的共显性模型(TT Vs CC)、隐性模型(TT Vs CT+CC)跟糖尿病视网膜病变的发生相关；而在白色人种中上述多态性位点与糖尿病视网膜病变无明显相关性。
(2)本省人群VEGF基因rs699947位点、VEGF基因rs833061位点、VEGF基因rs2010963位点的多态性变化在糖尿病视网膜病变发生发展中具有一定的意义
(3)VEGFXXX与EGFxxxb比值改变导致糖尿病视网膜病变的发生和发展。rs2010963位点多态性变化为功能性改变,对糖尿病患者发生糖尿病视网膜病变有重要意义。
(4)收缩压≥160mmHg舒张压≥90mmHg.糖化血红蛋白≥8.0mmol/L、肌酐值≥VEGF165>28mmol/L、rs2010963CC基因型及VEGF165b<5.0mmol/L为糖尿病视网膜病变发生的高危人群。
Objective:
The aim of this study is to discuss genetic and environmental predisposing factors of diabetic retinopathy (DR.) with type2diabetes in Hunan Province and screen the high-risk groups of diabetic retinopathy.
(1) To Search VEGF single nucleotide polymorphisms related to diabetic retinopathy in the yellow people by meta-analysis method.
(2) To investigate the susceptibility between VEGF single nucleotide polymorphisms and diabetic retinopathy in Hunan Province.
(3) To investigate correlation between serum VEGF total protein, isoform VEGF165and VEGF165b with diabetic retinopathy
(4)To explore the risk factors of diabetic retinopathy through comparing VEGF single nucleotide polymorphisms, VEGF protein and other demographic characteristics and biochemical parameters by case-control and logistic regression analysis.
Methods:
(1) Review relevant articles about the VEGF single nucleotide polymorphisms and diabetic retinopathy was carried out until March2012. A systematic search of electronic databases and access to the original literature, development of inclusion and exclusion criteria; and making a meta-analysis by the experimental data.
(2) According to the result of meta-analysis, detect VEGF single nucleotide polymorphisms among normal people, diabetic patients with no retinopathy and diabetic retinopathy patients by case-control method in Hunan Province,and do statistical analysis of distribution among the groups by the chi-square test.
(3) Enzyme-linked immunosorbent assay was used to detect serum total VEGF、VEGF165and VEGF165b among normal people, diabetic patients with no retinopathy and diabetic retinopathy in Hunan province. Do statistical analysis of distribution among them through group T-test and linear regression analysis and discuss correlation with VEGF single nucleotide polymorphisms and environmental factors.
(4) Investigate the susceptibility factors of diabetic retinopathy through a case-control based study among diabetic patients with no retinopathy and diabetic retinopathy on risk factor as demographic characteristics、biochemical parameters、VEGF single nucleotide polymorphisms and VEGF protein expression; Statistical analysis of data by group T-test and logistic regression analysis.
Results:
(1) Meta-analysis:
VEGF rs699947A significant association between it and DR risk was found in dominant model (CA Vs CC)(I2=64%,OR=1.27,95%CI[1.05,1.54],P=0.02),especially in the yellow race(I2=38%,OR=1.46,95%CI[1.17,1.82]p=0.0007).Other models with DR was no significant correlation.(P>0.05).
VEGF rs1570360All type of models with DR was no significant correlation.(P>0.05).
VEGF rs2010963A significant association between it and DR risk was found in recessive model(CC Vs GC+GG)in the yellow race group by subgroup analysis(I2=60%,OR=1.2895%CI[1.01,1.63],P=0.04)；and in recessive model(CC Vs GC+GG)by PCR-RFLR subgroup analysis(I2=46%,OR=1.5095%CI[1.05,2.14],P=0.03)
VEGF rs3025039A significant association between it and DR risk was found in co-dominant model (TT Vs CC)(I2=50%,OR=2.47,95%CI[1.11,5.51],P=0.03),especially in the yellow race(I2=51%, OR=3.5395%CI[1.35,9.26],P=0.01).Recessive model(TT Vs CT+CC)with DR was no significant correlation in the white race (P=0.05),but different in the yellow race(I2=33%,OR=3.1995%CI [1.21,8.42],P=0.01).Other models with DR was no significant correlation.(P>0.05).
(2)Frequencies of VEGF gene polymorphism genotype and allele between the DWR group and DR group in Hunan province:
VEGF rs699947:Frequencies of DR group AA genotype is14.8%, DWR group is4.3%; The CC genotype is48.1%in DR group, DWR group is60.9%(P=0.04,<0.05).The allele A frequency in the DR group is33.3%, and DWR group is21.7%(P=0.016,<0.05). The diabetes patients with rs699947AA genotype occurred the DR risk was3.83times higher than who with CC genotype and CA genotype (OR=3.83).
VEGF rs833061:Frequencies of DR group CC genotype is16.0%, DWR group is4.3%; The TT genotype is45.7%in DR group, DWR group is58.7%(P=0.025,<0.05).The allele C frequency in the DR group is35.2%, and DWR group is22.8%(P=0.011,<0.05). The diabetes patients with rs833061CC genotype occurred the DR risk was4.21times higher than who with TTgenotype and TC genotype (OR=4.21).
VEGF rs13207351:Frequencies of genotype and allele between the two groups had not statistically significant difference (P>0.05). All rs13207351genotype in patients with diabetes is no significant difference in the risk of DR.
VEGF rs2010963:Frequencies of DR group CC genotype is21.0%, DWR group is9.8%; The GG genotype is28.4%in DR group, DWR group is42.4%(P=0.049,<0.05).The allele C frequency in the DR group is46.3%, and DWR group is33.4%(P=0.017,<0.05). The diabetes patients with rs2010963CC genotype occurred the DR risk was2.45times higher than who with GG genotype and GC genotype (OR=2.45).
VEGF rs3025039:Frequencies of genotype and allele between the two groups had not statistically significant difference (P>0.05). All rs3025039genotype in patients with diabetes is no significant difference in the risk of DR.
(3) VEGF total protein,VEGF165and VEGF165b:
1) serum VEGF total protein was44.47±3.42(pg/ml) in normal control group,57.74±11.23(pg/ml) in the DWR group and59.25±11.62(pg/ml) in DR group.Compared with the control group, VEGF total protein in the DWR group and DR group was increased (P<0.05), but the total amount of VEGF between the DWR group and DR group was no statistically significant difference (P>0.05).
2) Serum VEGF165was15.89±1.31(pg/ml) in normal control group,22.68±4.52(pg/ml) in the DWR group and27.43±7.29(pg/ml) in DR group.Compared with the control group, VEGF165in the DWR group and DR group was increased (P<0.05).And VEGF165between the DWR group and DR group had statistically significant difference (P=0.025).
3) Serum VEGF165b was9.25±0.82(pg/ml) in normal control group,6.97±1.46(pg/ml) in the DWR group and5.43±2.35(pg/ml) in DR group. Content among the three groups showed a gradually decreasing trend, the difference was statistically significant (P<0.05). The ratio of of VEGF165and VEGF165b was changed among the three groups, and the ratio gradually increased (1.72,3.25,5.05).
4)The relationship between VEGF protein and VEGF gene: Compared with GG genotype and GA genotype, VEGF protein was significantly higher in the patients with rs2010963CC genotype (62.59±13.71(pg/ml) in the CC genotypes,53.27±10.37(pg/ml) in GA genotype,50.85±10.59(pg/ml) in GG genotype); and the difference had statistically significance (P<0.05).Other SNP genotypes had no statistically significant difference (P>0.05).
(4)The susceptibility factors of diabetic retinopathy:
1) Systolic blood pressure, diastolic blood pressure, glycosylated hemoglobin and creatinine between the two groups had a statistically significance to analyze demographic characteristics and biochemical parameters between DWR group and DR group by group T-test (P <0.05).
2) Logistic regression analysis:diabetic patients with systolic blood pressure over160mmHg had a7.5times higher DR risk than who with130mmHg; diabetic patients with diastolic blood pressure over90mmHg had a2times higher DR risk than who less to90mmHg. Diabetic patients with HbAIC over14.0%had11.50times higher DR risk than with who less to8%. Diabetic patients with Creatinine values above100mmol/L had5.5times higher DR risk than with who less to60mmol/L. Diabetic patients with rs2010963CC genotype had3.2times higher DR risk compared with GG genotype. Diabetic patients with VEGF165above28.0mmol/L had9.3times higher DR risk than with who less to28.0mmol/L. Diabetic patients with VEGF165b above5.0mmol/L had lower DR risk than with who less to5.0mmol/L (OR=0.013).VEGFi65b has a significant protective effect for people with diabetes.
5. Conclusions:
(1) The co-dominant model (CA Vs CC) of VEGF rs699947, the implicit model (CC Vs GC+GG) of VEGF rs2010963, the co-dominant model (TT Vs CT+CC) and the implicit model (TT Vs CC) of VEGF rs3025039, are associated with the occurrence of diabetic retinopathy in the yellow race, but have no obvious correlation diabetic retinopathy in the white race.
(2) The polymorphism variation of rs699947, rs833061and rs2010963of the VEGF gene has significance in the occurrence and development of diabetic retinopathy in the population of Hunan province.
(3) The change of the ratio of VEGFxxx and VEGFxxxb leads to the initiation and progression of diabetic retinopathy. The polymorphism variation of rs2010963is a functional change, which is important for occurrence of diabetic retinopathy in diabetic patients.
(4) People with SBP≥160mmHg, DBP≥90mmHg, glycosylated hemoglobin≥8.0mmol/L, Creatinine values≥100mmol/L,28mmol/L, rs2010963CC gene and VEGF165b<5.0mmol/L have high risk for diabetic retinopathy.
研究湖南地区2型糖尿病视网膜病变(diatetic retinopathy,DR)遗传及环境易感因素；筛选糖尿病视网膜病变发生的高危人群。
(1)采用荟萃分析方法,搜寻黄种人中与糖尿病视网膜病变发生相关的血管内皮生长因子(vascular endothelial growthfactor,VEGF)单核苷酸多态性位点。
(2)探讨湖南地区人群中VEGF单核苷酸多态性位点与糖尿病视网膜病变易感性的关联性。
(3)探讨血清中VEGF蛋白总量,亚型VEGF165及其异构体VEGF165b含量与糖尿病视网膜病变的相关性。
(4)采用病例对照及logistic回归分析比较VEGF单核苷酸多态性位点、VEGF蛋白及其他人口学特征和生化指标,探讨糖尿病视网膜病变发生的高危因素。
方法：
(1)回顾2012年3月前有关VEGF单核苷酸多态性与糖尿病视网膜病变的所有英文文献。系统性检索及获取原始文献、制定纳入及排除标准；将单核苷酸多态性位点与糖尿病视网膜病变相关的实验数据进行荟萃分析。
(2)根据荟萃分析显示黄种人中有意义的VEGF单核苷酸多态性位点,采用病例对照方法,使用限制性片段长度多态性聚合酶链反应(PCR-RFLR)检测其在湖南地区正常人、糖尿病无视网膜病变患者(diabetic without retinopathy, DWR)、糖尿病视网膜病变患者(diabetic retinopathy, DR)的分布,通过卡方检验统计分析其在各组间的分布差异。
(3)采用病例对照方式,使用酶联免疫吸附测定法检测湖南地区正常人,糖尿病无视网膜病变患者,糖尿病视网膜病变患者的血清中VEGF总量,亚型/EGF165及其异构体VEGF165b含量,通过成组T检验及线性回归分析统计分析其含量在各组间的分布差异,及与、/EGF单核苷酸多态性位点及环境因素间的关联性。
(4)采用病例对照方式,统计糖尿病无视网膜病变患者,糖尿病视网膜病变患者的人口学特征及生化指标的相关数据及VEGF单核苷酸多态性位点及VEGF蛋白表达,进行成组T检验及logistic回归分析,探讨糖尿病视网膜病发生的高危易感因素。
结果：
(1)荟萃分析结果：
VEGF rs699947共显性模型-杂合型／野生型(CAVs CC)与DR发病风险存在相关性(I2=64%, OR=1.2795%CI [1.05,1.54], P=0.02),尤其在黄色人种中(I2=38%, OR=1.4695%CI [1.17,1.82], P=0.0007)。其它模型与DR发病无显著相关性(P>0.05)
VEGF rs1570360各模型在各色人种中与DR的发病无显著相关性(P>0.05)。
VEGF rs2010963亚组分析：黄色人种组隐性模型(CC V s GC+GG)显示与DR的发病相关(I2=60%, OR=1.2895%CI [1.01,1.63], P=0.04); PCR-RFLR测序方式组隐性模型(CC V s GC+GG)与DR的发生明显相关(I2=46%, OR=1.5095%CI [1.05,2.14], P=0.03)
VEGF rs3025039共显性模型-纯和型／野生型(TT Vs CC)与DR发病风险存在相关性(I2=50%, OR=2.4795%CI [1.11,5.51], P=0.03),特别是在黄色人种中(I2=51%, OR=3.5395%CI [1.35,9.26], P=0.01)。隐性模型(TT Vs CT+CC)白色人种与DR发病无明显相关性(P=0.05),在黄色人种中示与DR的发生相关(I2=33%, OR=3.1995%CI [1.21,8.42], P=0.01);其它各模型与DR的发病无明显相关性(P>0.05)。
(2)本省人群中DWR组与DR组VEGF基因多态性位点基因型频率及等位基因频率：
VEGF基因rs699947位点：DR组AA基因型分布频率为14.8%,DWR组为4.3%；CC基因型DR组为48.1%,DWR组为60.9%(P=0.04,<0.05),其等位基因A频率在DR组为33.3%,DWR组为21.7%(P=0.016,<0.05)。携带rs699947AA基因型的糖尿病患者发生DR的危险性较rs699947CC基因型及CA基因型携带者高3.83倍(OR=3.83)。
VEGF基因rs833061位点：DR组CC基因型分布频率为16.0%,DWR组为4.3%；TT基因型DR组为45.7%,DWR组为58.7%(P=0.025,<0.05),其等位基因C频率在DR组为35.2%,DWR组为22.8%(P=0.011,<0.05)。携带rs833061CC基因型的糖尿病患者发生DR的危险性较rs833061TT基因型及TC基因型携带者高4.21倍(OR=4.21)。
VEGF基因rs13207351位点：基因型频率及等位基因频率在研究组和对照组间的差异无明显统计学意义(P>0.05)。携带rs13207351GG基因型、GA基因型及AA基因型的糖尿病患者发生DR的危险性没有明显差别。
VEGF基因rs2010963位点：DR组CC基因型分布频率为21.0%,DWR组为9.8%。GG基因型DR组为28.4%,DWR组为42.4%(P=0.049,<0.05),其等位基因C频率在DR组为46.3%,DWR组为33.4%(P=0.017,<0.05)。携带rs2010963CC基因型的糖尿病患者发生DR的危险性较rs2010963GG基因型及GC基因型携带者高2.45倍(OR=2.45)。
VEGF基因rs3025039位点：基因型频率及等位基因频率在研究组和对照组间的差异无明显统计学意义(P>0.05)。携带rs3025039CC基因型、CT基因型及TT基因型的糖尿病患者发生DR的概率没有明显统计差异。
(3) VEGF蛋白总量、VEGF165含量和VEGF165b含量：
1)正常对照组中血清VEGF总量为44.47±3.42(pg/ml), DWR组血清VEGF总量为57.74±11.23(pg/ml), DR组59.25±11.62(pg/ml),DWR组及DR组的VEGF总量都较正常对照组升高(P<0.05),但DWR组与DR组之间VEGF总量没有明显的统计学差异(P>0.05)。
2)正常对照组中VEGF165含量为15.89±1.31(pg/ml), DWR组为22.68±4.52(pg/ml); DR组为27.43±7.29(pg/ml),与正常对照组比具有统计学意义(P<0.05)；且VEGF165在D WR组及DR组之间也有显著差异(P=0.025)。
3)VEGF165b在血中的含量在正常对照组为9.25±0.82(pg/ml); DWR组为6.97±1.46(pg/ml); DR组为5.43±2.35(pg/ml).其含量在三组之间呈现逐渐降低的趋势,差异具有统计学意义(P<0.05)。VEGF165及VEGF165b的比值在三组间出现变化,比值逐渐增大(1.72、3.25、5.05)。
4)蛋白总量与基因位点：携带rs2010963CC基因型人群其血中VEGF蛋白含量较GG基因型及GA型显著增高(CC基因型VEGF蛋白含量为62.59±13.71(pg/ml),GA基因型蛋白含量为53.27±10.37(pg/ml),GG基因型蛋白含量为50.85±10.59(pg/ml));CC基因型与GG基因型及GC基因型比较均具有统计学上的显著性差异,P<0.05),其他各SNP位点各基因型之间无明显统计学差别(P>0.05)。
(4)糖尿病视网膜病变易感因素分析：
1)DWR组及DR组之间的人口学特征及生化指标的相关数据进行成组T检验,发现收缩压、舒张压、糖化血红蛋白及肌酐值在两组之间存在显著的统计学差异(P<0.05)。
2)logistic回归分析：收缩压高于160mmHg的糖尿病患者发生DR的危险性较低于130mmHg的高7.5倍,舒张压高于90mmHg的糖尿病患者发生DR的危险性较低于90mmHg的高2倍。HbAIC含量高于14.0%的糖尿病患者发生DR的危险性较低于8.0%的高11.50倍。肌酐值高于100mmol/L的糖尿病患者发生DR的危险性较低于60mmol/L的高出5.5倍。携带rs2010963CC基因型糖尿病患者发生DR的危险性较GG基因型患者高3.2倍。VEGF165含量高于28.0mmol/L的糖尿病患者发生DR的危险性较低于28.0mmol/L的患者高9.3倍,而VEGF165b含量高于5.0mmol/L的糖尿病患者发生DR的危险性较低于5.0mmol/L的患者明显降低(OR=0.013),VEGF165b对于糖尿病患者有明显保护作用。
结论：
(1)黄色人种中VEGF rs699947的共显性模型(C A Vs C C)、 VEGF rs2010963隐性模型(CC Vs GC+GG)及VEGF rs3025039的共显性模型(TT Vs CC)、隐性模型(TT Vs CT+CC)跟糖尿病视网膜病变的发生相关；而在白色人种中上述多态性位点与糖尿病视网膜病变无明显相关性。
(2)本省人群VEGF基因rs699947位点、VEGF基因rs833061位点、VEGF基因rs2010963位点的多态性变化在糖尿病视网膜病变发生发展中具有一定的意义
(3)VEGFXXX与EGFxxxb比值改变导致糖尿病视网膜病变的发生和发展。rs2010963位点多态性变化为功能性改变,对糖尿病患者发生糖尿病视网膜病变有重要意义。
(4)收缩压≥160mmHg舒张压≥90mmHg.糖化血红蛋白≥8.0mmol/L、肌酐值≥VEGF165>28mmol/L、rs2010963CC基因型及VEGF165b<5.0mmol/L为糖尿病视网膜病变发生的高危人群。
Objective:
The aim of this study is to discuss genetic and environmental predisposing factors of diabetic retinopathy (DR.) with type2diabetes in Hunan Province and screen the high-risk groups of diabetic retinopathy.
(1) To Search VEGF single nucleotide polymorphisms related to diabetic retinopathy in the yellow people by meta-analysis method.
(2) To investigate the susceptibility between VEGF single nucleotide polymorphisms and diabetic retinopathy in Hunan Province.
(3) To investigate correlation between serum VEGF total protein, isoform VEGF165and VEGF165b with diabetic retinopathy
(4)To explore the risk factors of diabetic retinopathy through comparing VEGF single nucleotide polymorphisms, VEGF protein and other demographic characteristics and biochemical parameters by case-control and logistic regression analysis.
Methods:
(1) Review relevant articles about the VEGF single nucleotide polymorphisms and diabetic retinopathy was carried out until March2012. A systematic search of electronic databases and access to the original literature, development of inclusion and exclusion criteria; and making a meta-analysis by the experimental data.
(2) According to the result of meta-analysis, detect VEGF single nucleotide polymorphisms among normal people, diabetic patients with no retinopathy and diabetic retinopathy patients by case-control method in Hunan Province,and do statistical analysis of distribution among the groups by the chi-square test.
(3) Enzyme-linked immunosorbent assay was used to detect serum total VEGF、VEGF165and VEGF165b among normal people, diabetic patients with no retinopathy and diabetic retinopathy in Hunan province. Do statistical analysis of distribution among them through group T-test and linear regression analysis and discuss correlation with VEGF single nucleotide polymorphisms and environmental factors.
(4) Investigate the susceptibility factors of diabetic retinopathy through a case-control based study among diabetic patients with no retinopathy and diabetic retinopathy on risk factor as demographic characteristics、biochemical parameters、VEGF single nucleotide polymorphisms and VEGF protein expression; Statistical analysis of data by group T-test and logistic regression analysis.
Results:
(1) Meta-analysis:
VEGF rs699947A significant association between it and DR risk was found in dominant model (CA Vs CC)(I2=64%,OR=1.27,95%CI[1.05,1.54],P=0.02),especially in the yellow race(I2=38%,OR=1.46,95%CI[1.17,1.82]p=0.0007).Other models with DR was no significant correlation.(P>0.05).
VEGF rs1570360All type of models with DR was no significant correlation.(P>0.05).
VEGF rs2010963A significant association between it and DR risk was found in recessive model(CC Vs GC+GG)in the yellow race group by subgroup analysis(I2=60%,OR=1.2895%CI[1.01,1.63],P=0.04)；and in recessive model(CC Vs GC+GG)by PCR-RFLR subgroup analysis(I2=46%,OR=1.5095%CI[1.05,2.14],P=0.03)
VEGF rs3025039A significant association between it and DR risk was found in co-dominant model (TT Vs CC)(I2=50%,OR=2.47,95%CI[1.11,5.51],P=0.03),especially in the yellow race(I2=51%, OR=3.5395%CI[1.35,9.26],P=0.01).Recessive model(TT Vs CT+CC)with DR was no significant correlation in the white race (P=0.05),but different in the yellow race(I2=33%,OR=3.1995%CI [1.21,8.42],P=0.01).Other models with DR was no significant correlation.(P>0.05).
(2)Frequencies of VEGF gene polymorphism genotype and allele between the DWR group and DR group in Hunan province:
VEGF rs699947:Frequencies of DR group AA genotype is14.8%, DWR group is4.3%; The CC genotype is48.1%in DR group, DWR group is60.9%(P=0.04,<0.05).The allele A frequency in the DR group is33.3%, and DWR group is21.7%(P=0.016,<0.05). The diabetes patients with rs699947AA genotype occurred the DR risk was3.83times higher than who with CC genotype and CA genotype (OR=3.83).
VEGF rs833061:Frequencies of DR group CC genotype is16.0%, DWR group is4.3%; The TT genotype is45.7%in DR group, DWR group is58.7%(P=0.025,<0.05).The allele C frequency in the DR group is35.2%, and DWR group is22.8%(P=0.011,<0.05). The diabetes patients with rs833061CC genotype occurred the DR risk was4.21times higher than who with TTgenotype and TC genotype (OR=4.21).
VEGF rs13207351:Frequencies of genotype and allele between the two groups had not statistically significant difference (P>0.05). All rs13207351genotype in patients with diabetes is no significant difference in the risk of DR.
VEGF rs2010963:Frequencies of DR group CC genotype is21.0%, DWR group is9.8%; The GG genotype is28.4%in DR group, DWR group is42.4%(P=0.049,<0.05).The allele C frequency in the DR group is46.3%, and DWR group is33.4%(P=0.017,<0.05). The diabetes patients with rs2010963CC genotype occurred the DR risk was2.45times higher than who with GG genotype and GC genotype (OR=2.45).
VEGF rs3025039:Frequencies of genotype and allele between the two groups had not statistically significant difference (P>0.05). All rs3025039genotype in patients with diabetes is no significant difference in the risk of DR.
(3) VEGF total protein,VEGF165and VEGF165b:
1) serum VEGF total protein was44.47±3.42(pg/ml) in normal control group,57.74±11.23(pg/ml) in the DWR group and59.25±11.62(pg/ml) in DR group.Compared with the control group, VEGF total protein in the DWR group and DR group was increased (P<0.05), but the total amount of VEGF between the DWR group and DR group was no statistically significant difference (P>0.05).
2) Serum VEGF165was15.89±1.31(pg/ml) in normal control group,22.68±4.52(pg/ml) in the DWR group and27.43±7.29(pg/ml) in DR group.Compared with the control group, VEGF165in the DWR group and DR group was increased (P<0.05).And VEGF165between the DWR group and DR group had statistically significant difference (P=0.025).
3) Serum VEGF165b was9.25±0.82(pg/ml) in normal control group,6.97±1.46(pg/ml) in the DWR group and5.43±2.35(pg/ml) in DR group. Content among the three groups showed a gradually decreasing trend, the difference was statistically significant (P<0.05). The ratio of of VEGF165and VEGF165b was changed among the three groups, and the ratio gradually increased (1.72,3.25,5.05).
4)The relationship between VEGF protein and VEGF gene: Compared with GG genotype and GA genotype, VEGF protein was significantly higher in the patients with rs2010963CC genotype (62.59±13.71(pg/ml) in the CC genotypes,53.27±10.37(pg/ml) in GA genotype,50.85±10.59(pg/ml) in GG genotype); and the difference had statistically significance (P<0.05).Other SNP genotypes had no statistically significant difference (P>0.05).
(4)The susceptibility factors of diabetic retinopathy:
1) Systolic blood pressure, diastolic blood pressure, glycosylated hemoglobin and creatinine between the two groups had a statistically significance to analyze demographic characteristics and biochemical parameters between DWR group and DR group by group T-test (P <0.05).
2) Logistic regression analysis:diabetic patients with systolic blood pressure over160mmHg had a7.5times higher DR risk than who with130mmHg; diabetic patients with diastolic blood pressure over90mmHg had a2times higher DR risk than who less to90mmHg. Diabetic patients with HbAIC over14.0%had11.50times higher DR risk than with who less to8%. Diabetic patients with Creatinine values above100mmol/L had5.5times higher DR risk than with who less to60mmol/L. Diabetic patients with rs2010963CC genotype had3.2times higher DR risk compared with GG genotype. Diabetic patients with VEGF165above28.0mmol/L had9.3times higher DR risk than with who less to28.0mmol/L. Diabetic patients with VEGF165b above5.0mmol/L had lower DR risk than with who less to5.0mmol/L (OR=0.013).VEGFi65b has a significant protective effect for people with diabetes.
5. Conclusions:
(1) The co-dominant model (CA Vs CC) of VEGF rs699947, the implicit model (CC Vs GC+GG) of VEGF rs2010963, the co-dominant model (TT Vs CT+CC) and the implicit model (TT Vs CC) of VEGF rs3025039, are associated with the occurrence of diabetic retinopathy in the yellow race, but have no obvious correlation diabetic retinopathy in the white race.
(2) The polymorphism variation of rs699947, rs833061and rs2010963of the VEGF gene has significance in the occurrence and development of diabetic retinopathy in the population of Hunan province.
(3) The change of the ratio of VEGFxxx and VEGFxxxb leads to the initiation and progression of diabetic retinopathy. The polymorphism variation of rs2010963is a functional change, which is important for occurrence of diabetic retinopathy in diabetic patients.
(4) People with SBP≥160mmHg, DBP≥90mmHg, glycosylated hemoglobin≥8.0mmol/L, Creatinine values≥100mmol/L,28mmol/L, rs2010963CC gene and VEGF165b<5.0mmol/L have high risk for diabetic retinopathy.
引文
[1]Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. Ⅱ. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102:520-526
[2]Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ⅲ.Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532
[3]Xie X, Xu L, Yang H, Wang S, Jonas JB. Frequency of diabetic retinopathy in the adult population in China:the Beijing Eye Study 2001.Int Ophthalmol.2009 Dec;29(6):485-93.
[4]Xie XW, Xu L, Wang YX, Jonas JB Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol.2008 Nov;246(11):1519-26.
[5]Tu Y, Xu L, Wei WB, Wang S, Wang YX, Jonas JB. Progression of diabetic retinopathy:the Beijing Eye Study.Chin Med J (Engl).2011 Nov; 124(22):3635-40.
[6]王宁,许迅.糖尿病视网膜病变相关基因多态性研究进展.中华眼科杂志,2005,42：563-566.
[7]Wang Y,Ng MC,Lee SC,et al.Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes.Diabetes Care,2003,26:2410-2415.
[8]LI Qingjie,XIE Ping,HUANG Jianjun,et al.Polymorphisms and functions of the aldose reductase gene 5'regulatory region in Chinese patients with type 2 diabetes mellitus.Chinese Medical Journal,2002,115:209-213.
[9]Kumaramanickavel G,Ramprasad VL,Sripriya S,et al.Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients.J Diabetes Complicat,2002,16:391-394.
[10]Awata, T.et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.Diabetes.2002.51(5):1635-1639.
[11]Suganthalakshmi B, Rajen D,Ran Anand,Ramasamy Kim et al.Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis. 2006.12:336-41
[12]Taverna MJ,Elgrably F,Selmi H,et al.The T-786C and C774T endothelial nitric oxide synthase gene polymorphisms independently affect the onset pattern of severe diabetic retinopathy.Nitric Oxide,2005,13:88-92.
[13]Matsumoto A,Iwashima Y,Abiko A,et al.Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy.Diabetes Res Clin Pract,2000,50:195-202.
[14]Kao Y,Donaghue K C,Chan A,et al.Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes.Diabet Med,2002,19:212-215.
[15]Neugebauer S,Baba T,Kurokawa K,et al.Defective homocysteine metabolism as a risk factor for diabetic retinopathy.Lancet,1997,349:473
[16]孙京华,陈艳艳,刘常明,等.维生素D受体TaqⅠ基因多态性与糖尿病性视网膜病变的关系.中华眼底病杂志,2003,22：94-96.
[17]Liu L,Yu Q,WangH,et al.Association of intercellular adhesion molecule 1 polymorphisms with retinopathy in Chinese patients with type 2 diabetes. Diabet Med,2006,23:643-648.
[18]Rietveld I,Ikram MK,Vingerling JR,et al.An igf-1 gene polymorphism modifies the risk of diabetic retinopathy.Diabetes,2006,55:2387-2391.
[19]FunkM,EndlerG,ExnerM,et al.PAI-14G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien Klin Wochenschr 2005,117:707-710.
[20]Jaakkola U,Pesonen U,Vainio-Jylha E,etal.TheLeu7Pro polymorphism of neu-Ropeptide Y is assocaubjects with diabetic retino-pathy.Exp Clin Endocrinol Diabetes,2006,114:147-152.
[21]Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes.Diabetes.2004 Mar;53(3):861-4.
[22]Monika B,Piotr K,Iwona BG,et al.Association of the VEGF gene polymo-rphism with diabetic retinopathy in type 2 diabetes patients.Nephrol Dial Transplant,2007,22:827-832.
[23]Yang B,CrossDF,Ollerenshaw M,et al.Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus.J Diabet Complicatt,2003,17:1-6.
[24]Szaflik JP, Wysocki T,Kowalski M,et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol.2008,246:39-43.
[25]Flavia Ⅳ,Luis HC,Maria ER,et al.Functional vascular endothelial growth factor-634G>C SNP is associated with proliferative diabetic retinopathy:A case-control study in a Brazilian population of European ancestry.Diabetes Care,2007,30:275-279.
[26]AI-Kateb H,Mirea L,Xie X,et al.. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes:the DCCT/EDIC genetics study. Diabetes 2007.56,2161-2168.
[27]Watson CJ,Webb NJ,Bottomeley MJ,et al.Indentification of polymorphism within the vascular endothelial growth factor(VEGF) gene:correlation with variation in VEGF protein production.Cytokine,2000,12:1232-1235.
[28]Simo R,Carrasco E,Garcia-Ramirez M,et al.Angiogenic and antiangio-genic factors in proliferative diabetic retinopathy. Curr Diabete Rev,2006,2:71-98.
[29]Mitamura Y,Harada C,Harada T. Role of cytokines and trophic factor in the pathogenesis of diabetic retinopathy.Curr Diabetes Rev,2005,1:73-81.
[30]Bates DO, Cui TG, Doughty JM, et al. VEGF 165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res,2002,62:4123-4131.
[31]Yang Y,Andresen B. T,Yang K,Zhang Y,Li X,Li X,Wang H. Association of vascular endothelial growth factor-634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese.Exp Biol Med.2010 oct 235(10):1204-11
[32]Feghhi, M., Nikzamir, A., Esteghamati, A., Mahmoudi, T., Yekaninejad, M.S.,2011. Relationship of vascular endothelial growth factor (VEGF)+405G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Transl. Res.158,85-91.
[33]Palmirotta R, Ferroni P, Ludovici G, Martini F, Savonarola A, D'Alessandro R, Raparelli V, Proietti M, Scarno A, Riondino S, Basili S, Guadagni F. VEGF gene promoter polymorphisms and microvascular complications in patients with essential hypertension.Clin Biochem.2010 Sep;43(13-14):1090-5.
[34]Errera FI et al.Functional vascular endothelial growth factor-634G/C SNP is associated with proliferative diabetic retinopathy:a case-control study in a Brazilian population of European ancestry. Diabetes Care.2007.30:275-279.
[35]Buraczynska M,Ksiazek P,Baranowicz-Gaszczyk I,Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients.Nephrol Dial Transplant.2007.22(3):827-32
[36]Zhao T, Zhao J. Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes:a meta-analysis. Diabetes Res.2010.90,45-53
[37]Paine SK, Basu A, Mondal LK, Sen A, Choudhuri S, Chowdhury IH, Saha A, Bhadhuri G, Mukherjee A, Bhattacharya B. Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes.Mol Vis. 2012;18:2749-57
[38]Awata, T, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem. Biophys. Res.2005.333:679-685.
[39]Churchill, A.J.et al., VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci.2008.49,3611-3616.
[40]Petrovic, M.Get al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol. Vis. 2008.14,1382-1387.
[41]Uthra, S., et al.,. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthalmic Genet.2008.29,11-15.
[42]Abhary, S., Hewitt, A.W., Burdon, K.P., Craig, J.E., A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009.58, 2137-2147.
[43]Kangas-Kontio, T., et al., Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. Br. J. Ophthalmol.2009.93,1401-1406.
[44]Kim, H. W, et al. Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients. Nephrology.2009.14(7): 681-688.
[45]Nakamura, S., Iwasaki, N., Funatsu, H., Kitano, S., Iwamoto, Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch.Clin. Exp. Ophthalmol.2009.247,21-26.
[46]Chun, M.Y, et al. Association of vascular endothelial growth factor polymorphisms with nonproliferative and proliferative diabetic retinopathy. J. Clin. Endocrinol.Metab.2010.95,3547-3551.
[47]Yang, X. et al. Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes.Mol. Vis. 2011.17,3088-3096.
[48]Min Qiu, Wei Xiong, Hui Liao, Feng Li. VEGF-634G>C polymorphism and diabetic retinopathy risk:A meta-analysis. Gene.2013.1-6
[49]Xu B, Feng NH, Tong N, Wang ZD, Zhang W, Wu HF, Hua LX. VEGF-460C>T polymorphism and cancer risk:a meta-analysis. Med Oncol 2010; 27:1031-6. [50] Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer research,2003.63:812-816
[51]Shahbazi M, Fryer AA, Pravica E, Brogan IJ, Ramsay HM,Hutchinson IV, Harden PN. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13:260-4.
[52]Szeto CC, Chow KM, Poon P, Szeto CYK,et al. Genetic polymorphism of VEGF:Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney International.2004.65:1947-1955
[53]Renner W. Kotschan S. Hoffmann C. Obermayer-Pietsch B. Pilger E. A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels.J Vasc Res 2000.37(6):443-448
[54]Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer,2003,106(4):468-471
[55]Gorin MB. The single-nucleotide polymorphisms +936 C/T VEGF and-710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Molecular Aspects of Medicine,2012.33(4):467-486
[56]Baharivand N, Zarghami N, Panahi F, Dokht Ghafari MY, Mahdavi Fard A, Mohajeri A..Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy. Clin Ophthalmol.2012;6:185-91.
[57]Perrin RM, Konopatskaya O, Qiu Y, et al. Diabetic retinopathy is associated with a switch in splicing from anti-to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia,2005,48:2422-2427.
[58]Engelgau M M, Thompson T J, Herman W H, et al. Comparison of fasting and 2-hour glucose and HbAlc levels fordiagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care,1997,20(5):785791.
[59]史琳涛,王爱红,许樟荣,王玉珍.糖尿病患者心血管病、肾病、眼底病变与血压及糖脂水平的关系.中华高血压杂志.2010.18(12)：1161-66
[60]伍春荣,马志中,胡莲娜,许樟荣,任正洪.糖尿病视网膜病变相关因素的因子分析.国际眼科杂志.2007.7(4)：1056-59
[61]Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ.The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol.2012 Sep 14; 11:109.
[62]Idiculla J, Nithyanandam S, Joseph M, Mohan VA, Vasu U, Sadiq M. Serum lipids and diabetic retinopathy:A cross-sectional study. Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S492-4.
[63]Sasongko MB, Wong TY, Nguyen TT, Kawasaki R, Jenkins AJ, Shaw J, Robinson C, Wang JJ. Serum apolipoproteins are associated with systemic and retinal microvascular function in people with diabetes. Diabetes.2012 Jul;61(7):1785-92.
[1]Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. Ⅱ. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526
[2]Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy.Ⅲ.Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532
[3]Klein R, Knudtson MD, Lee KE, Gangnon R Klein BE.The Wisconsin Epidemiologic Study of Diabetic Retinopathy:XXII the twenty-five-year progression of retinopathyin persons with type 1 diabetes. Ophthalmology.2008 Nov;115(11):1859-68
[4]West SK, Munoz B, Klein R, Broman AT, Sanchez R, Rodriguez J,Snyder R (2002) Risk factors for Type Ⅱ diabetes and diabetic retinopathy in a Mexican-American population:proyecto VER.Am J Ophthalmol 134:390-398
[5]Klein BE (2007) Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 14:179-183
[6]Crawford TN, Alfaro 3rd DV, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009;1:8-13.
[7]Rosman M, Zheng Y, Lamoureux E, Saw SM, Aung T, Tay WT, Wang JJ, Mitchell P, Tai ES, Wong TY. Review of key findings from the Singapore Malay Eye Study(SiMES-1).Singapore Med J.2012 Feb;53(2):82-7.
[8]Rosman M, Zheng Y, Wong W, Lamoureux E, Saw SM, Tay WT, Wang JJ, Mitchell P, Tai ES, Wong TY. Singapore Malay Eye Study:rationale and methodology of 6-year follow-up study (SiMES-2). Clin Experiment Ophthalmol.2012 Aug;40(6):557-68.
[9]Xie X, Xu L, Yang H, Wang S, Jonas JB. Frequency of diabetic retinopathy in the adult population in China:the Beijing Eye Study 2001.Int Ophthalmol.2009 Dec;29(6):485-93.
[10]Xie XW, Xu L, Wang YX, Jonas JB Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006.Graefes Arch Clin Exp Ophthalmol.2008 Nov;246(11):1519-26.
[11]Tu Y, Xu L, Wei WB, Wang S, Wang YX, Jonas JB. Progression of diabetic retinopathy:the Beijing Eye Study.Chin Med J (Engl).2011 Nov;124(22):3635-40.
[12]Frank, R.N. (2004) Diabetic retinopathy. N Engl. J. Med.2004 Jan 1;350,48-58
[13]Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus:the Oslo study. BMJ 1985;290:811-815
[14]Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria:a preliminary multicenter trial. N Engl J Med 1984 Aug 9;311(6):365-72.
[15]The Diabetes Control and Complications Trial Research Group(1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
[16]UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
[17]UK Prospective Diabetes Study (UKPDS) Group (2004) Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus (UKPDS 69). Arch Ophthalmol 122:1631-1640
[18]Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun.1989 Jun 15;161(2):851-8.
[19]Ferrara N:Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999,56:794-814.
[20]Ferrara N., H.P. Gerber, J. LeCouter, The biology of VEGF and its receptors, Nat. Med.9 (2003) 669-676.
[21]Vincenti V, Cassano C, Rocchi M, Persico G.Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation.1996 Apr 15;93(8):1493-5.
[22]Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.Science.1983 Feb 25;219(4587):983-5
[23]Gospodarowicz D, Abraham JA, Schilling J Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci U S A.1989 Oct;86(19):7311-5.
[24]Mineur P, Colige AC, Deroanne CF, Dubail J, Kesteloot F, Habraken Y, Noel A, Voo S, Waltenberger J, Lapiere CM, Nusgens BV, Lambert CA.Newly identified biologically active and proteolysis-resistant VEGF isoform VEGF111 is induced by genotoxic agents. J Cell Biol.2007 Dec 17; 179(6):1261-73.
[25]K.A. Houck, N. Ferrara, J. Winer, et al., The vascular endothelial growth factor family:identification of a fourth molecular species and characterization of alternative splicing of RNA, Mol. Endocrinol.5 (1991) 1806-1814.
[26]Whittle C, Gillespie K, Harrison R, Mathieson PW, Harper SJ. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin. Sci.1999;97:303-312.
[27]Lange T, Guttmann-Raviv N, Baruch L, Machluf M, Neufeld G. VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. J. Biol. Chem.2003;278:17164-17169.
[28]Jingjing L, Xue Y, Agarwal N, Roque RS. Human Miiller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest. Ophthalmol. Visual Sci.1999;40:752-759.
[29]Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N.1992. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037.
[30]Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA.1991.The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954.
[31]Bhisitkul, R.B. Vascular endothelial growth factor biology:clinical implications for ocular treatments. Br J Ophthalmol.2006 Dec;90(12):1542-7
[32]Saint-Geniez M, Maldonado AE, D'Amore PA VEGF expression and receptor activation in the choroid during developmentand in the adult.Invest Ophthalmol Vis Sci.2006 Jul;47(7):3135-42.
[33]Stewart EA, Samaranayake GJ, Browning AC, Hopkinson A, Amoaku WM Comparison of choroidal and retinal endothelial cells:characteristics andresponse to VEGF isoforms and anti-VEGF treatments. Exp Eye Res.2011 Nov;93(5):761-6.
[34]Cao J, McLeod S, Merges CA, Lutty GA.Choriocapillaris degeneration and related pathologic changes in humandiabetic ey es. Arch Ophthalmol.1998 May;116(5):589-97.
[35]Mohamed IN, Soliman SA, Alhusban A, Matragoon S, Pillai BA, Elmarkaby AA, El-Remessy AB.Diabetes exacerbates retinal oxidative stress, inflammation, and microvascular degeneration in spontaneously hypertensive rats. Mol Vis.2012;18:1457-66. Epub 2012 Jun 2
[36]Yonekura H, Sakurai S, Liu X, Migita H, Wang H, Yamagishi S, Nomura M, Abedin MJ, Unoki H, Yamamoto Y,Yamamoto H.. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem.1999 Dec 3;274(49):35172-8.
[37]Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med.1994;331:1480-1487.
[38]Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K.The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest.1996 Apr;74(4):819-25.
[39]Duh E, Aiello LP.Vascular endothelial growth factor and diabetes:the agonist versus antagonist paradox. Diabetes.1999 Oct;48(10):1899-906.
[40]Schmidt-Erfurth UM, Pruente C.Management of neovascular age-related macular degeneration. Prog Retin Eye Res.2007 Jul;26(4):437-51.
[41]Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM,Glassman AR, Scott IU, Stockdale CR,Sun JK; Diabetic Retinopathy Clinical Research Network.Expanded 2-year follow-up ofranibizumab plus prompt deferred laser ortriamcinolone plus prompt laser for diabetic macular edema. Ophthalmology.2011 Apr;118(4):609-14.
[42]Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T,Bunce C, Leslie RD, Hykin PG.A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data:report 2. Ophthalmology.2010 Jun;117(6):1078-1086
[43]Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA.Two-year results of randomized trial of intravitreal bevacizumab alone orcombined with tr iamcinolone versus laser in diabetic macular edema. Retina.2012 Feb;32 (2):314-21.
[44]Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ VEGF165b, an inhibitory splice variant of vascular endothelial growth factor,is down-regulated in renal cell carcinoma.Cancer Res.2002 Jul 15;62(14):4123-31.
[45]Rennel ES, Varey AH, Churchill AJ, Wheatley ER, Stewart L, Mather S, Bates DO, Harper SJ.VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF splice isoforms, inhibits neovascularisation and tumour growth in vivo. Br J Cancer.2009 Oct 6;101(7):1183-93.
[46]Miller-Kasprzak E, Jagodzinski PP.5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells. Biomed Pharmacother.2008 Mar;62(3):158-63. Epub 2007 Aug 23.
[47]Harper SJ, Bates DO.VEGF splicing:the key to anti-angiogenic therapeutics? Nat Rev Cancer.2008 Nov;8(11):880-7.
[48]Woolard J,Wang WY,Bevan HS,Qiu Y,Morbidelli L, Pritchard-Jones RO,Cui TG, Sugiono M,Waine E,Perrin R, Foster R,Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO.VEGF165b, an inhibitory vascular endothelial growth factor splice variant:mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res.2004 Nov1;64(21):7822-35.
[49]Cebe Suarez S, Pieren M, Cariolato L, Am S, Hoffmann U, Bogucki A, Manlius C, Wood J, Ballmer-Hofer K. A VEGF splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci.2006 Sep;63(17):2067-77.
[50]Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ.Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia.2005 Nov;48(11):2422-7. Epub 2005 Sep 29.
[51]Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA.VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis.2006 May 26;12:626-32.
[52]Hua J, Spee C, Kase S, et al. Recombinant human VEGF 165b inhibits experimental choroidal neovascularisation. Invest Ophthalmol Vis Sci,2010,51: 4282-4288.
[53]Misteli T, Caceres JF, Spector DL.The dynamics of a pre-mRNA splicing factor in living cells. Nature.1997 May 29;387(6632):523-7.
[54]Carter JG, Cherry J, Williams K, Turner S, Bates DO, Churchill AJSplicing factor polymorphisms, the control of VEGF isoforms and associationwith angiogenic eye disease. Curr Eye Res.2011 Apr;36(4):328-35.
[55]Caceres JF, Kornblihtt AR. Alternative splicing:multiple control mechanisms and involvement in human disease. Trends Genet.2002 Apr; 18(4):186-93.
[56]Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO Expression of pro- and anti- angiogenic isoforms of VEGF is differentiallyregulated by splicing and growth factors. J Cell Sci.2008 Oct 15;121(Pt 20):3487-95.
[57]Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ,Woolard J, Ladomery MR, Bates DO Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms:a novel therapeutic strategy for angiogenesis. J Biol Chem.2010 Feb 19;285(8):5532-40.
[2]Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ⅲ.Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532
[3]Xie X, Xu L, Yang H, Wang S, Jonas JB. Frequency of diabetic retinopathy in the adult population in China:the Beijing Eye Study 2001.Int Ophthalmol.2009 Dec;29(6):485-93.
[4]Xie XW, Xu L, Wang YX, Jonas JB Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefes Arch Clin Exp Ophthalmol.2008 Nov;246(11):1519-26.
[5]Tu Y, Xu L, Wei WB, Wang S, Wang YX, Jonas JB. Progression of diabetic retinopathy:the Beijing Eye Study.Chin Med J (Engl).2011 Nov; 124(22):3635-40.
[6]王宁,许迅.糖尿病视网膜病变相关基因多态性研究进展.中华眼科杂志,2005,42：563-566.
[7]Wang Y,Ng MC,Lee SC,et al.Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes.Diabetes Care,2003,26:2410-2415.
[8]LI Qingjie,XIE Ping,HUANG Jianjun,et al.Polymorphisms and functions of the aldose reductase gene 5'regulatory region in Chinese patients with type 2 diabetes mellitus.Chinese Medical Journal,2002,115:209-213.
[9]Kumaramanickavel G,Ramprasad VL,Sripriya S,et al.Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients.J Diabetes Complicat,2002,16:391-394.
[10]Awata, T.et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.Diabetes.2002.51(5):1635-1639.
[11]Suganthalakshmi B, Rajen D,Ran Anand,Ramasamy Kim et al.Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis. 2006.12:336-41
[12]Taverna MJ,Elgrably F,Selmi H,et al.The T-786C and C774T endothelial nitric oxide synthase gene polymorphisms independently affect the onset pattern of severe diabetic retinopathy.Nitric Oxide,2005,13:88-92.
[13]Matsumoto A,Iwashima Y,Abiko A,et al.Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy.Diabetes Res Clin Pract,2000,50:195-202.
[14]Kao Y,Donaghue K C,Chan A,et al.Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes.Diabet Med,2002,19:212-215.
[15]Neugebauer S,Baba T,Kurokawa K,et al.Defective homocysteine metabolism as a risk factor for diabetic retinopathy.Lancet,1997,349:473
[16]孙京华,陈艳艳,刘常明,等.维生素D受体TaqⅠ基因多态性与糖尿病性视网膜病变的关系.中华眼底病杂志,2003,22：94-96.
[17]Liu L,Yu Q,WangH,et al.Association of intercellular adhesion molecule 1 polymorphisms with retinopathy in Chinese patients with type 2 diabetes. Diabet Med,2006,23:643-648.
[18]Rietveld I,Ikram MK,Vingerling JR,et al.An igf-1 gene polymorphism modifies the risk of diabetic retinopathy.Diabetes,2006,55:2387-2391.
[19]FunkM,EndlerG,ExnerM,et al.PAI-14G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien Klin Wochenschr 2005,117:707-710.
[20]Jaakkola U,Pesonen U,Vainio-Jylha E,etal.TheLeu7Pro polymorphism of neu-Ropeptide Y is assocaubjects with diabetic retino-pathy.Exp Clin Endocrinol Diabetes,2006,114:147-152.
[21]Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes.Diabetes.2004 Mar;53(3):861-4.
[22]Monika B,Piotr K,Iwona BG,et al.Association of the VEGF gene polymo-rphism with diabetic retinopathy in type 2 diabetes patients.Nephrol Dial Transplant,2007,22:827-832.
[23]Yang B,CrossDF,Ollerenshaw M,et al.Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus.J Diabet Complicatt,2003,17:1-6.
[24]Szaflik JP, Wysocki T,Kowalski M,et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol.2008,246:39-43.
[25]Flavia Ⅳ,Luis HC,Maria ER,et al.Functional vascular endothelial growth factor-634G>C SNP is associated with proliferative diabetic retinopathy:A case-control study in a Brazilian population of European ancestry.Diabetes Care,2007,30:275-279.
[26]AI-Kateb H,Mirea L,Xie X,et al.. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes:the DCCT/EDIC genetics study. Diabetes 2007.56,2161-2168.
[27]Watson CJ,Webb NJ,Bottomeley MJ,et al.Indentification of polymorphism within the vascular endothelial growth factor(VEGF) gene:correlation with variation in VEGF protein production.Cytokine,2000,12:1232-1235.
[28]Simo R,Carrasco E,Garcia-Ramirez M,et al.Angiogenic and antiangio-genic factors in proliferative diabetic retinopathy. Curr Diabete Rev,2006,2:71-98.
[29]Mitamura Y,Harada C,Harada T. Role of cytokines and trophic factor in the pathogenesis of diabetic retinopathy.Curr Diabetes Rev,2005,1:73-81.
[30]Bates DO, Cui TG, Doughty JM, et al. VEGF 165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res,2002,62:4123-4131.
[31]Yang Y,Andresen B. T,Yang K,Zhang Y,Li X,Li X,Wang H. Association of vascular endothelial growth factor-634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese.Exp Biol Med.2010 oct 235(10):1204-11
[32]Feghhi, M., Nikzamir, A., Esteghamati, A., Mahmoudi, T., Yekaninejad, M.S.,2011. Relationship of vascular endothelial growth factor (VEGF)+405G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Transl. Res.158,85-91.
[33]Palmirotta R, Ferroni P, Ludovici G, Martini F, Savonarola A, D'Alessandro R, Raparelli V, Proietti M, Scarno A, Riondino S, Basili S, Guadagni F. VEGF gene promoter polymorphisms and microvascular complications in patients with essential hypertension.Clin Biochem.2010 Sep;43(13-14):1090-5.
[34]Errera FI et al.Functional vascular endothelial growth factor-634G/C SNP is associated with proliferative diabetic retinopathy:a case-control study in a Brazilian population of European ancestry. Diabetes Care.2007.30:275-279.
[35]Buraczynska M,Ksiazek P,Baranowicz-Gaszczyk I,Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients.Nephrol Dial Transplant.2007.22(3):827-32
[36]Zhao T, Zhao J. Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes:a meta-analysis. Diabetes Res.2010.90,45-53
[37]Paine SK, Basu A, Mondal LK, Sen A, Choudhuri S, Chowdhury IH, Saha A, Bhadhuri G, Mukherjee A, Bhattacharya B. Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes.Mol Vis. 2012;18:2749-57
[38]Awata, T, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem. Biophys. Res.2005.333:679-685.
[39]Churchill, A.J.et al., VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci.2008.49,3611-3616.
[40]Petrovic, M.Get al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol. Vis. 2008.14,1382-1387.
[41]Uthra, S., et al.,. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthalmic Genet.2008.29,11-15.
[42]Abhary, S., Hewitt, A.W., Burdon, K.P., Craig, J.E., A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009.58, 2137-2147.
[43]Kangas-Kontio, T., et al., Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. Br. J. Ophthalmol.2009.93,1401-1406.
[44]Kim, H. W, et al. Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients. Nephrology.2009.14(7): 681-688.
[45]Nakamura, S., Iwasaki, N., Funatsu, H., Kitano, S., Iwamoto, Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch.Clin. Exp. Ophthalmol.2009.247,21-26.
[46]Chun, M.Y, et al. Association of vascular endothelial growth factor polymorphisms with nonproliferative and proliferative diabetic retinopathy. J. Clin. Endocrinol.Metab.2010.95,3547-3551.
[47]Yang, X. et al. Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes.Mol. Vis. 2011.17,3088-3096.
[48]Min Qiu, Wei Xiong, Hui Liao, Feng Li. VEGF-634G>C polymorphism and diabetic retinopathy risk:A meta-analysis. Gene.2013.1-6
[49]Xu B, Feng NH, Tong N, Wang ZD, Zhang W, Wu HF, Hua LX. VEGF-460C>T polymorphism and cancer risk:a meta-analysis. Med Oncol 2010; 27:1031-6. [50] Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer research,2003.63:812-816
[51]Shahbazi M, Fryer AA, Pravica E, Brogan IJ, Ramsay HM,Hutchinson IV, Harden PN. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13:260-4.
[52]Szeto CC, Chow KM, Poon P, Szeto CYK,et al. Genetic polymorphism of VEGF:Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney International.2004.65:1947-1955
[53]Renner W. Kotschan S. Hoffmann C. Obermayer-Pietsch B. Pilger E. A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels.J Vasc Res 2000.37(6):443-448
[54]Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer,2003,106(4):468-471
[55]Gorin MB. The single-nucleotide polymorphisms +936 C/T VEGF and-710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Molecular Aspects of Medicine,2012.33(4):467-486
[56]Baharivand N, Zarghami N, Panahi F, Dokht Ghafari MY, Mahdavi Fard A, Mohajeri A..Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy. Clin Ophthalmol.2012;6:185-91.
[57]Perrin RM, Konopatskaya O, Qiu Y, et al. Diabetic retinopathy is associated with a switch in splicing from anti-to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia,2005,48:2422-2427.
[58]Engelgau M M, Thompson T J, Herman W H, et al. Comparison of fasting and 2-hour glucose and HbAlc levels fordiagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care,1997,20(5):785791.
[59]史琳涛,王爱红,许樟荣,王玉珍.糖尿病患者心血管病、肾病、眼底病变与血压及糖脂水平的关系.中华高血压杂志.2010.18(12)：1161-66
[60]伍春荣,马志中,胡莲娜,许樟荣,任正洪.糖尿病视网膜病变相关因素的因子分析.国际眼科杂志.2007.7(4)：1056-59
[61]Toth PP, Simko RJ, Palli SR, Koselleck D, Quimbo RA, Cziraky MJ.The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol.2012 Sep 14; 11:109.
[62]Idiculla J, Nithyanandam S, Joseph M, Mohan VA, Vasu U, Sadiq M. Serum lipids and diabetic retinopathy:A cross-sectional study. Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S492-4.
[63]Sasongko MB, Wong TY, Nguyen TT, Kawasaki R, Jenkins AJ, Shaw J, Robinson C, Wang JJ. Serum apolipoproteins are associated with systemic and retinal microvascular function in people with diabetes. Diabetes.2012 Jul;61(7):1785-92.
[1]Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. Ⅱ. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526
[2]Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy.Ⅲ.Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527-532
[3]Klein R, Knudtson MD, Lee KE, Gangnon R Klein BE.The Wisconsin Epidemiologic Study of Diabetic Retinopathy:XXII the twenty-five-year progression of retinopathyin persons with type 1 diabetes. Ophthalmology.2008 Nov;115(11):1859-68
[4]West SK, Munoz B, Klein R, Broman AT, Sanchez R, Rodriguez J,Snyder R (2002) Risk factors for Type Ⅱ diabetes and diabetic retinopathy in a Mexican-American population:proyecto VER.Am J Ophthalmol 134:390-398
[5]Klein BE (2007) Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 14:179-183
[6]Crawford TN, Alfaro 3rd DV, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009;1:8-13.
[7]Rosman M, Zheng Y, Lamoureux E, Saw SM, Aung T, Tay WT, Wang JJ, Mitchell P, Tai ES, Wong TY. Review of key findings from the Singapore Malay Eye Study(SiMES-1).Singapore Med J.2012 Feb;53(2):82-7.
[8]Rosman M, Zheng Y, Wong W, Lamoureux E, Saw SM, Tay WT, Wang JJ, Mitchell P, Tai ES, Wong TY. Singapore Malay Eye Study:rationale and methodology of 6-year follow-up study (SiMES-2). Clin Experiment Ophthalmol.2012 Aug;40(6):557-68.
[9]Xie X, Xu L, Yang H, Wang S, Jonas JB. Frequency of diabetic retinopathy in the adult population in China:the Beijing Eye Study 2001.Int Ophthalmol.2009 Dec;29(6):485-93.
[10]Xie XW, Xu L, Wang YX, Jonas JB Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006.Graefes Arch Clin Exp Ophthalmol.2008 Nov;246(11):1519-26.
[11]Tu Y, Xu L, Wei WB, Wang S, Wang YX, Jonas JB. Progression of diabetic retinopathy:the Beijing Eye Study.Chin Med J (Engl).2011 Nov;124(22):3635-40.
[12]Frank, R.N. (2004) Diabetic retinopathy. N Engl. J. Med.2004 Jan 1;350,48-58
[13]Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus:the Oslo study. BMJ 1985;290:811-815
[14]Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria:a preliminary multicenter trial. N Engl J Med 1984 Aug 9;311(6):365-72.
[15]The Diabetes Control and Complications Trial Research Group(1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
[16]UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
[17]UK Prospective Diabetes Study (UKPDS) Group (2004) Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus (UKPDS 69). Arch Ophthalmol 122:1631-1640
[18]Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun.1989 Jun 15;161(2):851-8.
[19]Ferrara N:Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999,56:794-814.
[20]Ferrara N., H.P. Gerber, J. LeCouter, The biology of VEGF and its receptors, Nat. Med.9 (2003) 669-676.
[21]Vincenti V, Cassano C, Rocchi M, Persico G.Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation.1996 Apr 15;93(8):1493-5.
[22]Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.Science.1983 Feb 25;219(4587):983-5
[23]Gospodarowicz D, Abraham JA, Schilling J Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci U S A.1989 Oct;86(19):7311-5.
[24]Mineur P, Colige AC, Deroanne CF, Dubail J, Kesteloot F, Habraken Y, Noel A, Voo S, Waltenberger J, Lapiere CM, Nusgens BV, Lambert CA.Newly identified biologically active and proteolysis-resistant VEGF isoform VEGF111 is induced by genotoxic agents. J Cell Biol.2007 Dec 17; 179(6):1261-73.
[25]K.A. Houck, N. Ferrara, J. Winer, et al., The vascular endothelial growth factor family:identification of a fourth molecular species and characterization of alternative splicing of RNA, Mol. Endocrinol.5 (1991) 1806-1814.
[26]Whittle C, Gillespie K, Harrison R, Mathieson PW, Harper SJ. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin. Sci.1999;97:303-312.
[27]Lange T, Guttmann-Raviv N, Baruch L, Machluf M, Neufeld G. VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. J. Biol. Chem.2003;278:17164-17169.
[28]Jingjing L, Xue Y, Agarwal N, Roque RS. Human Miiller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest. Ophthalmol. Visual Sci.1999;40:752-759.
[29]Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N.1992. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267:26031-26037.
[30]Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA.1991.The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954.
[31]Bhisitkul, R.B. Vascular endothelial growth factor biology:clinical implications for ocular treatments. Br J Ophthalmol.2006 Dec;90(12):1542-7
[32]Saint-Geniez M, Maldonado AE, D'Amore PA VEGF expression and receptor activation in the choroid during developmentand in the adult.Invest Ophthalmol Vis Sci.2006 Jul;47(7):3135-42.
[33]Stewart EA, Samaranayake GJ, Browning AC, Hopkinson A, Amoaku WM Comparison of choroidal and retinal endothelial cells:characteristics andresponse to VEGF isoforms and anti-VEGF treatments. Exp Eye Res.2011 Nov;93(5):761-6.
[34]Cao J, McLeod S, Merges CA, Lutty GA.Choriocapillaris degeneration and related pathologic changes in humandiabetic ey es. Arch Ophthalmol.1998 May;116(5):589-97.
[35]Mohamed IN, Soliman SA, Alhusban A, Matragoon S, Pillai BA, Elmarkaby AA, El-Remessy AB.Diabetes exacerbates retinal oxidative stress, inflammation, and microvascular degeneration in spontaneously hypertensive rats. Mol Vis.2012;18:1457-66. Epub 2012 Jun 2
[36]Yonekura H, Sakurai S, Liu X, Migita H, Wang H, Yamagishi S, Nomura M, Abedin MJ, Unoki H, Yamamoto Y,Yamamoto H.. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem.1999 Dec 3;274(49):35172-8.
[37]Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med.1994;331:1480-1487.
[38]Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K.The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest.1996 Apr;74(4):819-25.
[39]Duh E, Aiello LP.Vascular endothelial growth factor and diabetes:the agonist versus antagonist paradox. Diabetes.1999 Oct;48(10):1899-906.
[40]Schmidt-Erfurth UM, Pruente C.Management of neovascular age-related macular degeneration. Prog Retin Eye Res.2007 Jul;26(4):437-51.
[41]Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM,Glassman AR, Scott IU, Stockdale CR,Sun JK; Diabetic Retinopathy Clinical Research Network.Expanded 2-year follow-up ofranibizumab plus prompt deferred laser ortriamcinolone plus prompt laser for diabetic macular edema. Ophthalmology.2011 Apr;118(4):609-14.
[42]Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T,Bunce C, Leslie RD, Hykin PG.A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data:report 2. Ophthalmology.2010 Jun;117(6):1078-1086
[43]Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA.Two-year results of randomized trial of intravitreal bevacizumab alone orcombined with tr iamcinolone versus laser in diabetic macular edema. Retina.2012 Feb;32 (2):314-21.
[44]Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ VEGF165b, an inhibitory splice variant of vascular endothelial growth factor,is down-regulated in renal cell carcinoma.Cancer Res.2002 Jul 15;62(14):4123-31.
[45]Rennel ES, Varey AH, Churchill AJ, Wheatley ER, Stewart L, Mather S, Bates DO, Harper SJ.VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF splice isoforms, inhibits neovascularisation and tumour growth in vivo. Br J Cancer.2009 Oct 6;101(7):1183-93.
[46]Miller-Kasprzak E, Jagodzinski PP.5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells. Biomed Pharmacother.2008 Mar;62(3):158-63. Epub 2007 Aug 23.
[47]Harper SJ, Bates DO.VEGF splicing:the key to anti-angiogenic therapeutics? Nat Rev Cancer.2008 Nov;8(11):880-7.
[48]Woolard J,Wang WY,Bevan HS,Qiu Y,Morbidelli L, Pritchard-Jones RO,Cui TG, Sugiono M,Waine E,Perrin R, Foster R,Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO.VEGF165b, an inhibitory vascular endothelial growth factor splice variant:mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res.2004 Nov1;64(21):7822-35.
[49]Cebe Suarez S, Pieren M, Cariolato L, Am S, Hoffmann U, Bogucki A, Manlius C, Wood J, Ballmer-Hofer K. A VEGF splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci.2006 Sep;63(17):2067-77.
[50]Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ.Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia.2005 Nov;48(11):2422-7. Epub 2005 Sep 29.
[51]Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA.VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis.2006 May 26;12:626-32.
[52]Hua J, Spee C, Kase S, et al. Recombinant human VEGF 165b inhibits experimental choroidal neovascularisation. Invest Ophthalmol Vis Sci,2010,51: 4282-4288.
[53]Misteli T, Caceres JF, Spector DL.The dynamics of a pre-mRNA splicing factor in living cells. Nature.1997 May 29;387(6632):523-7.
[54]Carter JG, Cherry J, Williams K, Turner S, Bates DO, Churchill AJSplicing factor polymorphisms, the control of VEGF isoforms and associationwith angiogenic eye disease. Curr Eye Res.2011 Apr;36(4):328-35.
[55]Caceres JF, Kornblihtt AR. Alternative splicing:multiple control mechanisms and involvement in human disease. Trends Genet.2002 Apr; 18(4):186-93.
[56]Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO Expression of pro- and anti- angiogenic isoforms of VEGF is differentiallyregulated by splicing and growth factors. J Cell Sci.2008 Oct 15;121(Pt 20):3487-95.
[57]Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ,Woolard J, Ladomery MR, Bates DO Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms:a novel therapeutic strategy for angiogenesis. J Biol Chem.2010 Feb 19;285(8):5532-40.